Loading…

Loading grant details…

Active HORIZON European Commission

Identification of cellular regulators and pharmacological inhibitors of endophilin-A3 to modulate its endocytic functions


Funder European Commission
Recipient Organization Universite de Namur
Country Belgium
Start Date Jun 01, 2024
End Date May 31, 2026
Duration 729 days
Number of Grantees 2
Roles Associated Partner; Coordinator
Data Source European Commission
Grant ID 101151524
Grant Description

In addition to classical clathrin-mediated endocytosis, mammalian cells have clathrin-independent endocytic (CIE) mechanisms. Among others, the BAR domain proteins, that sense and induce membrane curvature, are key players in CIE.

In particular, the BAR domain protein endophilin-A3 (endoA3) drives CIE of the cell adhesion molecules CD166, L1CAM, and DICAM, with implications in tumour progression and viral infection.

The regulation, mechanism, and functional implications of this recently-identified endoA3-mediated CIE route remain poorly characterized.

In this context, I propose an interdisciplinary project combining cell biology, chemical biology, and virology approaches to substantially advance our understanding of endoA3-mediated CIE.

The first research goal is to identify cellular regulators (kinases, phosphoinositides) that modulate endoA3-mediated endocytosis.

In parallel, this project aims at identifying small molecule inhibitors that selectively inhibit the endocytic functions of endoA3.

Subsequently, the cellular regulators and pharmacological inhibitors identified in this project will be used in cells, to modulate endoA3-mediated endocytosis and study the impact on cellular functions. Emphasis will be put on cancer cell properties and endocytic viral particle entry.

Together, this project will generate high-quality fundamental knowledge on the mechanism and function of endoA3-mediated CIE.

Moreover, the identification of modulators of endoA3 endocytic functions will provide valuable biological tools for the study of this recently-identified CIE route in physiology and pathology.

Lastly, the identification of selective pharmacological inhibitors may pave the way towards the development of innovative antiviral and anti-cancer therapeutics targeted at unconventional endocytosis. This fellowship will be conducted in the laboratory of Prof. Henri-Francois Renard (UNamur, Belgium), who has been a pioneer in the identification of BAR-mediated endocytic routes.

All Grantees

Centre National de la Recherche Scientifique CNRS; Universite de Namur

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant